Increasing the levels of AEA and 2-AG in the brain with the use of inhibitors of the main degrading enzymes, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), has been documented as an effective strategy to control the immune response in different models of MS, Huntington’s disease (HD) and AD. This evidence concerns the gene MGLL and myeloid sarcoma.